Video | Agriculture | Confidence | Economy | Energy | Employment | Finance | Media | Property | RBNZ | Science | SOEs | Tax | Technology | Telecoms | Tourism | Transport | Search


Chairman appointed to new biotech company

13 August 2004

Chairman appointed to new biotech company

Bio-Strategy Group has appointed Bruce McKinnon as chairman, to access his 25 years’ international and local experience in the biotech and chemicals industries.

Mr McKinnon says he is excited by the potential he has seen in Bio-Strategy, with its unique combination of practical distribution expertise, and biotech and business consultation.

“For a new company, Bio-Strategy has already made waves through its value-added approach to distribution and its science-to-market know how. Being able to help guide a company with such strength and vision is a privilege and I look forward to the challenge of assisting Bio-Strategy establish itself as a market leader.”

Mr McKinnon has 15 years’ experience in the chemicals industry with Rhone Poulenc, working in New Zealand, England, Australia and France. He joined Salmond Smith Biolab in 1994 and subsequently took over as Group CEO for Biolab Scientific Limited. During his 10 years in this role he managed the development of this laboratory products business from being a New Zealand only distributor to the largest laboratory products distributor in Australasia. He managed the sale of this business to Alesco Corporation in 2003.


© Scoop Media

Business Headlines | Sci-Tech Headlines


Media Mega Merger: StuffMe Hearing Argues Over Moveable Feast

New Zealand's two largest news publishers are appealing against the Commerce Commission's rejection of the proposal to merge their operations. More>>


Approval: Northern Corridor Decision Released

The approval gives the green light to construction of the last link of Auckland’s Western Ring Route, providing an alternative route from South Auckland to the North Shore. More>>


Crown Accounts: $4.1 Billion Surplus

The New Zealand Government has achieved its third fiscal surplus in a row with the Crown accounts for the year ended 30 June 2017 showing an OBEGAL surplus of $4.1 billion, $2.2 billion stronger than last year, Finance Minister Steven Joyce says. More>>


Mycoplasma Bovis: One New Property Tests Positive

The newly identified property... was already under a Restricted Place notice under the Biosecurity Act. More>>

Accounting Scandal: Suspension Of Fuji Xerox From All-Of-Government Contract

General Manager of New Zealand Government Procurement John Ivil says, “FXNZ has been formally suspended from the Print Technology and Associated Services (PTAS) contract and terminated from the Office Supplies contract.” More>>